Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtros adicionais

País/Região como assunto
Intervalo de ano
J Exp Med ; 214(9): 2563-2572, 2017 Sep 04.
Artigo em Inglês | MEDLINE | ID: mdl-28724616


Until recently, immune responses in filovirus survivors remained poorly understood. Early studies revealed IgM and IgG responses to infection with various filoviruses, but recent outbreaks have greatly expanded our understanding of filovirus immune responses. Immune responses in survivors of Ebola virus (EBOV) and Sudan virus (SUDV) infections have provided the most insight, with T cell responses as well as detailed antibody responses having been characterized. Immune responses to Marburg virus (MARV), however, remain almost entirely uncharacterized. We report that immune responses in MARV survivors share characteristics with EBOV and SUDV infections but have some distinct differences. MARV survivors developed multivariate CD4+ T cell responses but limited CD8+ T cell responses, more in keeping with SUDV survivors than EBOV survivors. In stark contrast to SUDV survivors, rare neutralizing antibody responses in MARV survivors diminished rapidly after the outbreak. These results warrant serious consideration for any vaccine or therapeutic that seeks to be broadly protective, as different filoviruses may require different immune responses to achieve immunity.

Anticorpos Neutralizantes/imunologia , Doença do Vírus de Marburg/imunologia , Marburgvirus/imunologia , Células Th1/imunologia , Adolescente , Adulto , Animais , Anticorpos Antivirais/imunologia , Linfócitos T CD4-Positivos/imunologia , Ligante de CD40/metabolismo , Linfócitos T CD8-Positivos/imunologia , Citocinas/metabolismo , Feminino , Citometria de Fluxo , Humanos , Imunidade Celular/imunologia , Masculino , Doença do Vírus de Marburg/mortalidade , Pessoa de Meia-Idade , Sobreviventes , Uganda/epidemiologia , Adulto Jovem